Parkinson's disease incidence and prevalence assessment in <scp>F</scp>rance using the national healthcare insurance database

Blin, Patrick; Dureau-Pournin, Caroline; Foubert‐Samier, Alexandra; Grolleau, A.; Corbillon, E.; Jové, Jérémy; Lassalle, R.; Robinson, Philip; Poutignat, N.; Droz–Perroteau, C.; Moore, Nicholas

doi:10.1111/ene.12592

Cited by 59 publications

(53 citation statements)

References 15 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our incidence rates are higher than those of Blin, Dureau‐Pournin9 who also used claims data in France and different validation strategies based on ICD codes and drug prescriptions. In contrast to our approach, this French study required a PD diagnosis to be confirmed by two different physicians.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Parkinson's disease in Germany: prevalence and incidence based on health claims data

2016

View full text Add to dashboard Cite

BackgroundIn Germany, epidemiological information on Parkinson's disease (PD) is rare and outdated. Considering aging populations, current prevalences and incidence rates about this age‐related disease would be important for adequate public health planning.MethodsWe used newly available health claims data sets from the largest German health insurer dating 2004‐2007 and 2007‐2010 with an analysis population in the base years of 491 038 persons aged 50 and older. Quarter‐specific information about ICD‐10 diagnoses and PD drug prescriptions from the inpatient and outpatient sectors was used to validate PD cases. Estimations were presented for two validation strategies relying on repeated PD diagnoses (SIa) and on one PD diagnosis followed by at least one PD drug prescription (SIb).ResultsThe standardized prevalence was 797 (SIb) to 961/100 000 persons (SIa), showing an age‐specific increase up to category 85‐89 and a decline thereafter. The standardized incidence rate was 192 to 229/100 000 person‐years with a similar age‐specific shape. Prevalences and incidences rates were higher for men compared to women in regard to age.ConclusionsHealth claims data are found to be suitable for PD assessment using the repeated diagnoses or PD drug prescriptions as necessary criteria.

show abstract

Section: Discussionmentioning

confidence: 70%

“…Generally, PD is rare before age 60 (0.13%‐1.6%), increases with age, and can reach a maximum of 9% among people aged 80‐84. Thereafter (85‐89), prevalences decline and vary from 0.87% to 3.6% 3, 4, 5, 6, 7, 8, 9, 10. Incidence rates are also low for those aged 50‐59 and increase sharply afterward.…”

Section: Introductionmentioning

confidence: 99%

Parkinson's disease in Germany: prevalence and incidence based on health claims data

2016

View full text Add to dashboard Cite

show abstract

“…Since 2010, French healthcare databases have been increasingly used for epidemiological purposes [7]. In addition to demographics and LTD status for MS, further data are now available in these databases, namely, reimbursements for disease-modifying treatments, disability pensions for MS, and hospitalisation for MS.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

Foulon¹,

Maura²,

Dalichampt³

et al. 2017

J Neurol

View full text Add to dashboard Cite

Data on the prevalence of multiple sclerosis (MS) in France are scarce. National and regional updated estimates are needed to better plan health policies. In this nationwide study, we provided estimates of the prevalence of MS in France in 2012 and mortality rate in 2013. MS cases were identified in the French national health insurance database (SNIIRAM-PMSI) using reimbursement data for disease-modifying treatment, long-term disease status for MS, disability pension for MS, and hospitalisation for MS (MS ICD-10 code: G35). We identified 99,123 MS cases, corresponding to an overall crude prevalence rate of 151.2 per 100,000 inhabitants [95% confidence interval (CI) 150.3–152.2]: 210.0 per 100,000 in women (95% CI 208.4–211.5) and 88.7 per 100,000 in men (95% CI 87.6–89.7). The overall prevalence rate was 155.6 per 100,000 inhabitants (95% CI 154.7–156.6) after standardization on the 2013-European population. We observed a prevalence gradient with a higher prevalence (190–200 per 100,000) in North-Eastern France and a lower prevalence in Southern and Western France (126–140). The crude mortality rate in 2013 was 13.7 per 1,000 MS cases (11.4 in women and 20.3 in men). The standardized mortality ratio was 2.56 (95% CI 2.41–2.72). Our results revise upwards the estimation of MS prevalence in France and confirm the excess mortality of MS patients compared to the general population.Electronic supplementary materialThe online version of this article (doi:10.1007/s00415-017-8513-0) contains supplementary material, which is available to authorized users.

show abstract

“…[13][14][15] The existing body of research on PD epidemiology suggests that disease frequency peaks in the age-group 80-89 years old and then declines; 5,16,17 other studies have found the highest agespecific prevalence rates among the oldest groups studied. [13][14][15] The existing body of research on PD epidemiology suggests that disease frequency peaks in the age-group 80-89 years old and then declines; 5,16,17 other studies have found the highest agespecific prevalence rates among the oldest groups studied.…”

mentioning

confidence: 98%

“…[13][14][15] The existing body of research on PD epidemiology suggests that disease frequency peaks in the age-group 80-89 years old and then declines; 5,16,17 other studies have found the highest agespecific prevalence rates among the oldest groups studied. 3,7,11,14,15,[17][18][19] Several other studies did not observe a statistically significant difference between gender and adjusted PD prevalence rates. Males have been related to higher age-adjusted prevalence rates in many studies; in only a few studies did females have higher rates.…”

mentioning

confidence: 98%

The increasing prevalence of Parkinson's disease in Estonia

et al. 2018

View full text Add to dashboard Cite

show abstract

Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database

Abstract: The specific and sensitive definitions of disease bracket the true values; the relatively small range indicates that the current study provides good estimations of incidence and prevalence of Parkinson's disease for recent years in France.

Cited by 59 publications

References 15 publications

Parkinson's disease in Germany: prevalence and incidence based on health claims data

Parkinson's disease in Germany: prevalence and incidence based on health claims data

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

The increasing prevalence of Parkinson's disease in Estonia

Contact Info

Product

Resources

About